ArticleTransfusion medicine (Oxford, England)2021
Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction.
Article in Transfusion medicine (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- European society for organ transplantation clinical practice guideline on prevention and treatment of chronic lung allograft dysfunction.Transplant international : official journal of the European Society for Organ Transplantation · 2026Guideline
- Quantitative CT monitoring of extracorporeal photopheresis response in chronic lung allograft dysfunction: A retrospective case series.Respiratory medicine case reports · 2026Article
- Identification of Surrogate Outcome Biomarkers in Lung Allograft Recipients With Bronchiolitis Obliterans: Implications for Randomized Controlled Trials.Transplantation direct · 2025Article
- Extracorporeal Photopheresis in Lung Transplantation: Present Applications and Emerging Research.Transplantation direct · 2025Article
- Article
- Chronic Lung Allograft Dysfunction: Clinical Manifestations and Immunologic Mechanisms.Transplantation · 2025Review
- Article
- Management of Busulfan-Induced Lung Injury in Pediatric Patients with High-Risk Neuroblastoma.Journal of clinical medicine · 2024Article
- Lymphocyte Depleting and Modulating Therapies for Chronic Lung Allograft Dysfunction.Pharmacological reviews · 2023Review
- A European Multi-Center Analysis of Extracorporeal Photopheresis as Therapy for Chronic Lung Allograft Dysfunction.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients.Transplant infectious disease : an official journal of the Transplantation Society · 2022Observational
- Article
- Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction.Transfusion medicine (Oxford, England) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 9 institutions in 2 countries.
Funding
Abstract
backgroundThis study was designed to prospectively evaluate the efficacy of extracorporeal photopheresis (ECP) to attenuate the rate of decline of FEV STUDY DESIGN AND
methodsSubjects from 10 lung transplant centres were assigned to ECP treatment or to observation based on spirometric criteria, with potential crossover for those under observation. The primary endpoint of this study was to assess response to ECP (i.e., greater than a 50% decrease in the rate of FEV
resultsOf 44 enrolled subjects, 31 were assigned to ECP treatment while 13 were initially assigned to observation on a non-random basis using specific spirometric inclusion criteria (seven of the observation patients subsequently crossed over to receive ECP). Of evaluable patients, 95% of patients initially assigned to treatment responded to ECP with rates of FEV
conclusionsThese analyses suggest that earlier detection and treatment of BOS should be considered to appreciate improved outcomes with ECP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.